Experimental cell therapy for cervical cancer stalls after just 5 patients
NCT ID NCT05357027
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new treatment called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. TC-E202 uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells. The trial was terminated early after enrolling only 5 participants, so we have very limited information about how safe or effective this approach might be.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TC-E202 cells (genetically engineered T cells targeting HPV16 E6)
What this could lead to
If successful, this approach could point toward a new treatment option for advanced cervical cancer that has not responded to standard therapies.
What could go wrong
This was a very early, small trial (only 5 participants) that was terminated early, so we have very little data on safety or effectiveness. The treatment also requires strong chemotherapy and IL-2, which can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiaochun Cheng
Chongqing, Chongqing Municipality, 400000, China